Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy Planning, Computer-Assisted | 2 | 2025 | 99 | 1.740 |
Why?
|
| Radiosurgery | 6 | 2025 | 147 | 1.580 |
Why?
|
| Organs at Risk | 1 | 2025 | 42 | 0.930 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2025 | 111 | 0.880 |
Why?
|
| Quality Assurance, Health Care | 1 | 2024 | 215 | 0.770 |
Why?
|
| Brain Neoplasms | 4 | 2025 | 1378 | 0.760 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2019 | 22 | 0.600 |
Why?
|
| Lung Neoplasms | 7 | 2022 | 1536 | 0.590 |
Why?
|
| Radiotherapy Dosage | 3 | 2025 | 237 | 0.580 |
Why?
|
| Brachytherapy | 1 | 2019 | 95 | 0.560 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2020 | 32 | 0.330 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2020 | 33 | 0.320 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 1576 | 0.320 |
Why?
|
| Mastectomy | 2 | 2020 | 75 | 0.320 |
Why?
|
| Arteriovenous Fistula | 2 | 2020 | 55 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 333 | 0.270 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2020 | 167 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 767 | 0.230 |
Why?
|
| Regression Analysis | 1 | 2025 | 795 | 0.210 |
Why?
|
| Retrospective Studies | 13 | 2025 | 17374 | 0.200 |
Why?
|
| Hippocampus | 2 | 2024 | 815 | 0.180 |
Why?
|
| Computer Simulation | 1 | 2024 | 696 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 602 | 0.170 |
Why?
|
| Radiation Oncology | 1 | 2020 | 28 | 0.160 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 72 | 0.160 |
Why?
|
| Treatment Outcome | 6 | 2022 | 12994 | 0.160 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 37 | 0.160 |
Why?
|
| Kallikreins | 1 | 2019 | 30 | 0.150 |
Why?
|
| Pneumonectomy | 1 | 2020 | 148 | 0.150 |
Why?
|
| Mesothelioma | 1 | 2020 | 93 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2166 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 301 | 0.140 |
Why?
|
| Corticotrophs | 1 | 2017 | 2 | 0.140 |
Why?
|
| Organ Size | 1 | 2019 | 447 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 271 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2019 | 365 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 2645 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 208 | 0.130 |
Why?
|
| Risk | 1 | 2019 | 761 | 0.130 |
Why?
|
| Neoplasm Staging | 4 | 2022 | 1361 | 0.130 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 78 | 0.130 |
Why?
|
| Humans | 17 | 2025 | 131929 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 958 | 0.130 |
Why?
|
| Prostate | 1 | 2019 | 437 | 0.120 |
Why?
|
| Adenoma | 1 | 2017 | 146 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1304 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 3830 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2021 | 6569 | 0.110 |
Why?
|
| Aged | 6 | 2020 | 21387 | 0.100 |
Why?
|
| Middle Aged | 6 | 2020 | 28945 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 5408 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 392 | 0.070 |
Why?
|
| Time Factors | 1 | 2019 | 6440 | 0.070 |
Why?
|
| Male | 7 | 2020 | 64872 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 1127 | 0.060 |
Why?
|
| Adult | 3 | 2019 | 31538 | 0.050 |
Why?
|
| Lung | 2 | 2021 | 1555 | 0.050 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2021 | 12 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2022 | 124 | 0.040 |
Why?
|
| Female | 7 | 2020 | 70586 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 20535 | 0.040 |
Why?
|
| Perfusion | 1 | 2021 | 208 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 5163 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2020 | 200 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2019 | 157 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2019 | 158 | 0.030 |
Why?
|
| Hypopituitarism | 1 | 2017 | 18 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2019 | 389 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2020 | 3139 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1293 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 1458 | 0.030 |
Why?
|
| Machine Learning | 1 | 2020 | 345 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1572 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2186 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 9952 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1439 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3011 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1342 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2221 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 3375 | 0.020 |
Why?
|
| Child | 2 | 2020 | 25761 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 5007 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 7097 | 0.020 |
Why?
|